S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Transition Therapeutics Stock Price, Forecast & Analysis (NASDAQ:TTHI)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume70,238 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:TTHI
CUSIPN/A
Phone+1-416-2607770

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive TTHI News and Ratings via Email

Sign-up to receive the latest news and ratings for TTHI and its competitors with MarketBeat's FREE daily newsletter.


Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions

What is Transition Therapeutics' stock symbol?

Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."

Has Transition Therapeutics been receiving favorable news coverage?

Media headlines about TTHI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Transition Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Transition Therapeutics.

What other stocks do shareholders of Transition Therapeutics own?

What is Transition Therapeutics' official website?

The official website for Transition Therapeutics is http://www.transitiontherapeutics.com/.

How can I contact Transition Therapeutics?

Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.


MarketBeat Community Rating for Transition Therapeutics (NASDAQ TTHI)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe TTHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Featured Article: Monthly Dividend Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel